IL-1靶向治疗在皮肤科疾病中的应用
本文综述IL-1靶向治疗在皮肤科疾病中的证据。IL-1阻断对冷吡啉相关周期性综合征、Schnitzler综合征等具疾病修饰作用,对IL-1受体拮抗剂缺陷和难治性坏疽性脓皮病高效,但在化脓性汗腺炎、脓疱型银屑病等中疗效异质。
要点
- IL-1阻断是冷吡啉相关周期性综合征和Schnitzler综合征的疾病修饰治疗。
- 对IL-1受体拮抗剂缺陷和激素难治性坏疽性脓皮病高效。
- 在化脓性汗腺炎、脓疱型银屑病中疗效异质,需谨慎评估。
核心结论
- IL-1拮抗剂对部分IL-1驱动性疾病不可或缺,是部分中性粒细胞性皮肤病的合理挽救选择。
研究设计与样本
- 本文为综述,未报告系统检索范围与样本量。
主要发现
- IL-1阻断对冷吡啉相关周期性综合征等单基因周期性发热综合征有强证据支持。
- 对Schnitzler综合征可快速控制荨麻疹性和中性粒细胞性皮疹。
- 队列和系列数据显示对IL-1受体拮抗剂缺陷和激素难治性坏疽性脓皮病高效。
- 在化脓性汗腺炎、脓疱型银屑病和PSTPIP1相关自身炎症性疾病中获益更异质。
- IL-36受体拮抗剂缺陷、SAPHO综合征、Sweet综合征和VEXAS综合征仅有个案报道或理论依据。
临床怎么用
- 选择IL-1拮抗剂时需结合临床表型,尽可能进行遗传学表型分析。
- 需关注儿童和成人剂量及安全性等实际考虑。
局限性
- 部分疾病证据仅来自散发病例报告或理论推理,反应高度可变或不确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Interleukin-1 (IL-1) plays a key role in inflammasome activation, keratinocyte signaling and neutrophil recruitment, and is a driving force behind many neutrophil-rich and suppurative dermatoses. There is robust evidence supporting the use of IL-1 blockade as a disease-modifying therapy in cryopyrin-associated periodic syndromes and other monogenic periodic fever syndromes, as well as in the treatment of Schnitzler syndrome, where it can rapidly control urticarial and neutrophilic eruptions. Cohort- and series-level data demonstrate high efficacy in IL-1 receptor antagonist deficiency and steroid-refractory pyoderma gangrenosum, whereas benefits appear more heterogeneous in hidradenitis suppurativa, pustular psoriasis and proline-serine-threonine phosphatase-interacting protein 1-associated autoinflammatory diseases. In contrast, conditions such as IL-36 receptor antagonist deficiency, synovitis acne pustulosis hyperostosis osteitis syndrome, Sweet syndrome and vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome are supported only by scattered case reports or theoretical rationale, with highly variable or uncertain responses to IL-1 blockade, highlighting the importance of careful clinical and, where possible, genetic phenotyping. We summarize practical considerations for selecting agents, pediatric and adult dosing and safety. IL-1 antagonists are indispensable for a subset of IL-1-driven disorders and represent a rational rescue option for selected neutrophilic dermatoses.
引用
- Balan K, Elston DM. IL-1-targeted therapy in dermatologic conditions. J Am Acad Dermatol. 2026. PMID: 42264383. doi:10.1016/j.jaad.2026.06.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。